Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide

被引:59
作者
Braga, Antonio [1 ,2 ]
Mora, Paulo [1 ,3 ]
de Melo, Andreia Cristina [3 ]
Nogueira-Rodrigues, Angelica [4 ]
Amim-Junior, Joffre [2 ]
Rezende-Filho, Jorge [2 ]
Seckl, Michael J. [5 ]
机构
[1] Fluminense Fed Univ, Postgrad Program Med Sci, BR-24033900 Niteroi, RJ, Brazil
[2] Rio de Janeiro Fed Univ, Fac Med, Dept Gynecol & Obstet, Postgrad Program Perinatal Hlth,Matern Sch, Rua Laranjeiras 180, BR-22240000 Rio De Janeiro, Brazil
[3] Hosp Canc 2, Brazilian Natl Canc, BR-20220410 Rio De Janeiro, Brazil
[4] Minas Gerais Fed Univ, Fac Med, Dept Internal Med, BR-30130100 Belo Horizonte, MG, Brazil
[5] Imperial Coll London, Charing Cross Hosp, Charing Cross Gestat Trophoblast Dis Ctr, Dept Med Oncol, London W6 8RF, England
关键词
Gestational trophoblastic neoplasia; Chemotherapy; Chorionic gonadotropin; Invasive mole; Choriocarcinoma; Placental site trophoblastic tumor; Epithelioid trophoblastic tumor; COMPLETE HYDATIDIFORM MOLE; UTERINE EVACUATION; 2ND CURETTAGE; DISEASE; MANAGEMENT; RISK; CHEMOTHERAPY; PREGNANCY; TUMORS; WOMEN;
D O I
10.5306/wjco.v10.i2.28
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases. The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics (FIGO) 2000 criteria: four or more plateaued human chorionic gonadotropin (hCG) concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However, the latter reason for treatment is no longer used by many centers. In addition, GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1 cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate (MTX) or Actinomycin-D (Act-D), can cure about 70% of patients with FIGO/World Health Organization (WHO) prognosis risk score >= 6 (low risk), reserving multiple agent chemotherapy, such as EMA/CO (Etoposide, MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score >= 7 (high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death, allow the healing and maintenance of the reproductive potential of these women.
引用
收藏
页码:28 / 37
页数:10
相关论文
共 56 条
[1]   Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study [J].
Agarwal, Roshan ;
Teoh, Suliana ;
Short, Delia ;
Harvey, Richard ;
Savage, Philip M. ;
Seckl, Michael J. .
LANCET, 2012, 379 (9811) :130-135
[2]   EMA/CO for High-Risk Gestational Trophoblastic Neoplasia: Good Outcomes With Induction Low-Dose Etoposide-Cisplatin and Genetic Analysis [J].
Alifrangis, Constantine ;
Agarwal, Roshan ;
Short, Delia ;
Fisher, Rosemary A. ;
Sebire, Neil J. ;
Harvey, Richard ;
Savage, Philip M. ;
Seckl, Michael J. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :280-286
[3]  
[Anonymous], COCHRANE DATABASE SY
[4]  
Bagshawe KD, 2006, J REPROD MED, V51, P849
[5]   Current advances in the management of gestational trophoblastic disease [J].
Berkowitz, Ross S. ;
Goldstein, Donald Peter .
GYNECOLOGIC ONCOLOGY, 2013, 128 (01) :3-5
[6]   Diagnosis, classification and treatment of gestational trophoblastic neoplasia [J].
Biscaro, Andressa ;
Braga, Antonio ;
Berkowitz, Ross Stuart .
REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2015, 37 (01) :42-51
[7]   PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes [J].
Bolze, Pierre-Adrien ;
Patrier, Sophie ;
Massardier, Jerome ;
Hajri, Touria ;
Abbas, Fatima ;
Schott, Anne Marie ;
Allias, Fabienne ;
Devouassoux-Shisheboran, Mojgan ;
Freyer, Gilles ;
Golfier, Francois ;
You, Benoit .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (03) :554-561
[8]   Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review [J].
Braga, A. ;
Maesta, I. ;
Short, D. ;
Savage, P. ;
Harvey, R. ;
Seckl, M. J. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2016, 123 (08) :1330-1335
[9]   Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? [J].
Braga, Antonio ;
Biscaro, Andressa ;
do Amaral Giordani, Jessye Melgarejo ;
Viggiano, Mauricio ;
Elias, Kevin M. ;
Berkowitz, Ross S. ;
Seckl, Michael J. .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 223 :50-55
[10]   Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? [J].
Braga, Antonio ;
Campos, Vanessa ;
Rezende Filho, Jorge ;
Lin, Lawrence H. ;
Sun, Sue Yazaki ;
de Souza, Christiani Bisinoto ;
Alves Ferreira da Silva, Rita de Cassia ;
Soares Leal, Elaine Azevedo ;
Silveira, Eduardo ;
Maesta, Izildinha ;
Madi, Jose Mauro ;
Uberti, Elza H. ;
Viggiano, Mauricio ;
Elias, Kevin M. ;
Horowitz, Neil ;
Berkowitz, Ross S. .
GYNECOLOGIC ONCOLOGY, 2018, 148 (02) :239-246